Article on MOA of BET inhibition restoring sensitivity to anti-androgen therapy

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Article on MOA of BET inhibition restoring sensitivity to anti-androgen therapy

posted on Sep 18, 2017 02:21PM

Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer.

Nice article published last week in eLife that provides interesting detail on the mechanism of action by which pan-BET inhibitors (they used JQ1) restore sensitivity to anti-androgen therpay (like enzalutamide) in prostate cancer. All consistent with the rational of Zenith's trial design. Thanks for originally alerting us to that Aureus on IV. Myopia LOL.